公开(公告)号：US09499868B2

公开(公告)日：2016-11-22

申请号：US14467954

申请日：2014-08-25

申请人： Amir Tchelet ,  Fabio Macciardi ,  Joseph Levy

发明人： Amir Tchelet ,  Fabio Macciardi ,  Joseph Levy

IPC分类号： A61K38/16 ,  C12Q1/68 ,  A61K45/06

CPC分类号： C12Q1/6883 ,  A61K38/02 ,  A61K38/16 ,  A61K45/06 ,  C12Q2600/106 ,  C12Q2600/156

摘要： This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.

摘要翻译： 本发明提供了一种治疗患有多发性硬化的人类受试者或与多发性硬化一致的单一临床攻击的方法，所述药物组合物包含乙酸格拉默和药学上可接受的载体，包括以下步骤：1）鉴定人受试者是否为预测 通过在选自组1中的SNP的一个或多个单核苷酸多态性（SNP）上确定受试者的基因型来响应乙酸格拉司坦; 以及2）如果将受试者鉴定为乙酸格拉默的预测应答者，则向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。

公开(公告)号：US20150045306A1

公开(公告)日：2015-02-12

申请号：US14467954

申请日：2014-08-25

申请人： Amir Tchelet ,  Fabio Macciardi ,  Joseph Levy

发明人： Amir Tchelet ,  Fabio Macciardi ,  Joseph Levy

IPC分类号： C12Q1/68 ,  A61K45/06 ,  A61K38/16

CPC分类号： C12Q1/6883 ,  A61K38/02 ,  A61K38/16 ,  A61K45/06 ,  C12Q2600/106 ,  C12Q2600/156

摘要： This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.

摘要翻译： 本发明提供了一种治疗患有多发性硬化的人类受试者或与多发性硬化一致的单一临床攻击的方法，所述药物组合物包含乙酸格拉默和药学上可接受的载体，包括以下步骤：1）鉴定人受试者是否为预测 通过在选自组1中的SNP的一个或多个单核苷酸多态性（SNP）上确定受试者的基因型来响应乙酸格拉司坦; 以及2）如果将受试者鉴定为乙酸格拉默的预测应答者，则向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。

公开(公告)号：US20150275302A1

公开(公告)日：2015-10-01

申请号：US14674606

申请日：2015-03-31

申请人： Mario Masellis ,  Joanne Knight ,  Maureen Shannon Collinson ,  Anthony Edward Lang ,  James Lowery Kennedy ,  Joseph Levy ,  Amir Tchelet ,  Iris Grossman ,  Eli Eyal ,  Ofra Barnett

发明人： Mario Masellis ,  Joanne Knight ,  Maureen Shannon Collinson ,  Anthony Edward Lang ,  James Lowery Kennedy ,  Joseph Levy ,  Amir Tchelet ,  Iris Grossman ,  Eli Eyal ,  Ofra Barnett

IPC分类号： C12Q1/68 ,  A61K45/06 ,  A61K31/4985 ,  A61K31/48 ,  A61K31/198 ,  A61K31/4045 ,  A61K31/428 ,  A61K31/381 ,  A61K31/135 ,  A61K31/439

CPC分类号： C12Q1/6883 ,  A61K31/135 ,  A61K31/198 ,  A61K31/381 ,  A61K31/4045 ,  A61K31/428 ,  A61K31/439 ,  A61K31/48 ,  A61K31/4985 ,  A61K45/06 ,  C12Q2600/106 ,  C12Q2600/156 ,  A61K2300/00

摘要： This application provides a method for treating a human subject afflicted with Parkinson's disease (PD) with a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and a pharmaceutically acceptable carrier, comprising the steps of: (i) obtaining a biological sample comprising a genome from the human subject afflicted with Parkinson's disease; (ii) assaying the DNA or RNA of the biological sample from the human subject using a probe or a primer, to determine the diploid genotype of the human subject at single nucleotide polymorphism (SNP) rs1076560 or rs2283265; (iii) identifying the human subject as a predicted responder to rasagiline if the diploid genotype is CC at rs1076560, CC at rs2283265, or CC at both rs1076560 and rs2283265; and (iv) administering the pharmaceutical composition comprising rasagiline and a pharmaceutically acceptable carrier to the human subject if the human subject is identified as a predicted responder to rasagiline.

摘要翻译： 本申请提供了用药物组合物治疗患有帕金森病（PD）的人类受试者的方法，所述药物组合物包含雷沙吉兰或雷沙吉兰的药学上可接受的盐和药学上可接受的载体，包括以下步骤：（i）获得包含 来自人类受试者患有帕金森病的基因组; （ii）使用探针或引物从人受试者测定生物样品的DNA或RNA，以确定单核苷酸多态性（SNP）rs1076560或rs2283265处人受试者的二倍体基因型; （iii）如果二倍体基因型是rs1076560的CC，rs2283265的CC或rs1076560和rs2283265的CC，则将人受试者鉴定为雷沙吉兰的预测应答者; 和（iv）如果人类受试者被鉴定为雷沙吉兰的预测应答者，则向人类受试者施用包含雷沙吉兰和药学上可接受的载体的药物组合物。

公开(公告)号：US09702007B2

公开(公告)日：2017-07-11

申请号：US14520280

申请日：2014-10-21

申请人： Amir Tchelet ,  Michael Hayden ,  Liat Hayardeny ,  Colin James Douglas Ross ,  Iris Grossman ,  David Ladkani

发明人： Amir Tchelet ,  Michael Hayden ,  Liat Hayardeny ,  Colin James Douglas Ross ,  Iris Grossman ,  David Ladkani

IPC分类号： A61K38/16 ,  C12Q1/68

CPC分类号： C12Q1/6883 ,  A61K38/02 ,  A61K38/16 ,  C12Q2600/106 ,  C12Q2600/156

摘要： The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2, one or more C alleles at the location of Group 3, one or more G alleles at the location of Group 4, or one or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.